Changing Landscape of EGFR+ mNSCLC
Repeat Testing at Progression of EGFR+ NSCLC
Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC
Practical Implications of the RELAY Trial in EGFR+ NSCLC
Treatment Options for EGFR+ NSCLC
Molecular Testing for Newly Diagnosed NSCLC
Improved Outcomes for Patients With EGFR+ NSCLC
A 68-Year-Old Man With Metastatic EGFR+ NSCLC
John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.
Characteristics of Additional KRAS Subsets in Lung Cancer
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.